[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100345493":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":39,"collaborators":7,"id":41,"slug":7,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Eisai Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Rufinamide","Rufinamide up to 45 milligram per kilogram per day (mg\u002Fkg\u002Fday).",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Eisai Medical Information","CONTACT","1-888-274-2378","esi_medinfo@eisai.com",[20,31],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":7},"Generała Tadeusza Kościuszki 52","AVAILABLE","Kielce","Poland",{"type":26,"coordinates":27},"Point",[28,29],20.62752,50.87033,{"lat":29,"lon":28},{"facility":32,"status":22,"city":33,"state":7,"zip":7,"country":24,"cosmosGeoPoint":34,"geoPoint":38,"contacts":7},"Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu","Poznan",{"type":26,"coordinates":35},[36,37],16.92993,52.40692,{"lat":37,"lon":36},{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100345493",false,"NCT03778424","An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303","An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome","Inclusion Criteria:\n\n* Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.\n\nExclusion Criteria:\n\n* Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.","ALL","4 Years","EXPANDED_ACCESS","This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.",[52],"Lennox Gastaut Syndrome",[54,55,11,56,57,58],"Central Nervous System","E2080","Epilepsy","Seizures","Brain Diseases","2025-07-14",{"date":61,"type":62},"2025-07-17","ACTUAL",{"name":5,"class":6},2]